Anti-PD-1
Phase 1Biologic
Anti-PD-1 is one of 80 biologic programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 1.
2
Indications
6
Total Trials
2
Active Trials
79
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Imjudo
AstraZenecaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
ABI-007
Bristol-Myers SquibbPhase 3
Carboplatin/paclitaxel
AstraZenecaPhase 3
Vusolimogene Oderparepvec
YYana Najjar
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Isolated Limb Perfusion
MMemorial Sloan Kettering Cancer Center
Phase 3
Allovectin-7
VVical
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Solid Tumors2 trials
Recurrent1 trial
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02658981·63 enrolled
Pancreatic Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-PD-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCorbus Pharmaceuticals Inc.